INFLIXCOVID
The INFLIXCOVID study is a randomized, controlled, multicenter, open label phase II clinical study
to evaluate infliximab in the treatment of patients with severe COVID-19 disease.
The sponsor of the study is the Universitätsklinikum Jena.